- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04226404
CSD190501: A Study to Determine Subject Puffing Patterns of an Electronic Nicotine Delivery System in an Ambulatory Setting
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Potential subjects will complete a pre-screening interview and a Screening Visit to assess their eligibility and, based on meeting eligibility requirements, will be enrolled into the study on the same day of the Screening Visit.
Once enrolled, the subjects will be assigned to one of the seven flavor variants of ENDS product. Subjects will be allowed to sample flavors and determine which flavor that they would like to use for the length of the study. Subjects will then participate in a three-week ambulatory study in which they will use their assigned IP in place of their UB ENDS. Subjects will be directed to not use their UB ENDS products during the study.
At the initial visit, subjects will be provided an orientation to the product, including the IP power unit, cartridges, the Product Use and Behavior (PUB) instrument, PUB application, and a provided electronic device. Based upon their UB ENDS usage, they will be given a sufficient amount (for three weeks of ad libitum use equaling 375% of their self-reported UB weekly use) of ENDS cartridges. The study will involve a one-week acclimation period followed by a two-week product use evaluation period. At the end of the first week of the study, subjects will receive a phone call from the clinic to assess IP compliance and to ensure that they are not using their UB ENDS. The PUB instrument will collect topography data, and product use data will be uploaded frequently using a web-based PUB application installed on the electronic device provided by the Sponsor. Throughout the study, subjects will receive weekly phone calls to remind them of guidelines for using their assigned IP. Subjects will be instructed to use the IP in place of their UB ENDS, but they will be allowed to use non-ENDS tobacco/nicotine-containing products according to their normal use pattern. All used cartridges may be disposed of by the subject.
At the conclusion of the three-week ambulatory period, subjects will return to the clinic; return the IP power unit, charger, all unused cartridges, the PUB instrument (and all cables/charger), and the provided electronic device. Each subject will complete all End of Study procedures, including completing the Product Evaluation Scale (PES) questionnaire, and they will then be discharged from the study.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37920
- New Orleans Center for Clinical Research (NOCCR)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to read, understand, and willing to sign an informed consent form (ICF) and complete questionnaires written in English.
- Generally healthy male or female, ≥21 years of age, inclusive, at the time of consent.
- Positive urine cotinine test at Screening.
- Cartridge-based, closed-system ENDS are the primary form of tobacco/nicotine-containing products used within 30 days of Screening. Subjects may be users of other tobacco/nicotine-containing products. If the subject is a dual/poly user of tobacco/nicotine-containing products then the subject must self report that a cartridge-based, closed-system ENDS is their primary product.
- Must have used 2 or more ENDS cartridges per week over the last 30 days. Brief periods of abstinence due to illness, quit attempt (prior to 30 days of Screening), or clinical study participation (prior to 30 days of Screening) will be allowed at the discretion of the Principal Investigator (PI).
- Females must be willing to use a form of contraception acceptable to the PI from the time of signing the ICF until the end of the study.
- Must be willing to use the assigned IP and only the assigned flavor as their exclusive source of ENDS use for the full duration of the three-week ambulatory period. Use of other non-ENDS tobacco/nicotine-containing products will be permitted during the ambulatory period.
- Must have familiarity with modern electronic devices such as an IOS/Android smart phone or tablet computer ("tablet") and be willing to be provided an electronic device, that allows for both Bluetooth connectivity and internet connectivity and be willing to keep both active for the length of the study.
- Must be willing to use an application on the provided electronic device, and keep the application active for the length of the study.
Exclusion Criteria:
- Presence of clinically significant uncontrolled cardiovascular, pulmonary, renal, hepatic, endocrine, gastrointestinal, psychiatric, hematological, neurological disease, or any other concurrent disease or medical condition that, in the opinion of the PI, makes the study participant unsuitable to participate in this clinical study.
- History or presence of diabetes.
- Systolic blood pressure of > 160 mmHg or a diastolic blood pressure of > 95 mmHg, measured after being seated for five minutes, with exceptions at the PI's discretion.
- Scheduled treatment for asthma currently or within the past consecutive 12 months prior to the Screening-Enrollment Visit. As-needed treatment, such as inhalers, may be included at the PI's discretion pending approval from the Medical Monitor.
- Any history of cancer, except for primary cancers of skin such as localized basal cell/squamous cell carcinoma that has been surgically and/or cryogenically removed.
- Use of any medication or substance that aids in smoking cessation, including but not limited to any nicotine replacement therapy (NRT, e.g., nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract within (≤) 30 days prior to the signing of informed consent.
- Participation in another clinical trial within (≤) 30 days prior to signing the ICF. The 30-day window for each subject will be derived from the date of the last study event in the previous study to the time of signing the ICF in the current study.
- Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.
- Individuals ≥ 35 years of age currently using systemic, estrogen-containing contraception or hormone replacement therapy.
- A positive urine drug screen without evidence of prescribed corresponding concomitant medication(s) at Screening.
- Postpones a decision to quit using tobacco/nicotine-containing products in order to participate in this study or a previous attempt within (≤) 30 days prior to the signing of the ICF.
- Drinks more than 21 servings of alcoholic beverages per week or has a positive alcohol breathalyzer result at Screening.
- Determined by the PI to be inappropriate for this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CSD1905-11
Subjects will be assigned to flavor variant CSD1905-11 of 4.8% ENDS products based on their preferred flavor.
|
Flavor variant CSD1905-11 of a 4.8% nicotine ENDS product
|
Experimental: CSD1905-12
Subjects will be assigned to flavor variant CSD1905-12 of 4.8% ENDS products based on their preferred flavor.
|
Flavor variant CSD1905-12 of a 4.8% nicotine ENDS product
|
Experimental: CSD1905-13
Subjects will be assigned to flavor variant CSD1905-13 of 4.8% ENDS products based on their preferred flavor.
|
Flavor variant CSD1905-13 of a 4.8% nicotine ENDS product
|
Experimental: CSD1905-14
Subjects will be assigned to flavor variant CSD1905-14 of 4.8% ENDS products based on their preferred flavor.
|
Flavor variant CSD1905-14 of a 4.8% nicotine ENDS product
|
Experimental: CSD1905-15
Subjects will be assigned to flavor variant CSD1905-15 of 4.8% ENDS products based on their preferred flavor.
|
Flavor variant CSD1905-15 of a 4.8% nicotine ENDS product
|
Experimental: CSD1905-16
Subjects will be assigned to flavor variant CSD1905-16 of 4.8% ENDS products based on their preferred flavor.
|
Flavor variant CSD1905-16 of a 4.8% nicotine ENDS product
|
Experimental: CSD1905-17
Subjects will be assigned to flavor variant CSD1905-17 of 4.8% ENDS products based on their preferred flavor.
|
Flavor variant CSD1905-17 of a 4.8% nicotine ENDS product
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Arithmetic Mean
Time Frame: 2 weeks
|
Arithmetic Mean puff duration
|
2 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CSD190501
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Smoking
-
University of Southern CaliforniaAmerican Cancer Society, Inc.CompletedSmoking | Smoking Cessation | Smoking, Cigarette | Smoking Behaviors | Cessation, SmokingUnited States
-
University of VirginiaRecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking, Cigarette | Quitting SmokingUnited States
-
Columbia UniversityNational Cancer Institute (NCI)RecruitingSmoking | Smoking Cessation | Smoking Reduction | Smoking BehaviorsUnited States
-
National Cancer Institute (NCI)CompletedSmoking | Smoking Cessation | Cigarette Smoking | Tobacco, SmokingUnited States
-
University GhentRecruitingSmoking | Smoking Tobacco | Smoking Prevention | Smoking CigaretteBelgium
-
Medical University of South CarolinaCompletedSmoking | Smoking Cessation | Smoking, Tobacco | Smoking, CigaretteUnited States
-
Maastricht University Medical CenterThe Investigative Desk; SEO Amsterdam Economics; IVO Research InstituteEnrolling by invitationSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsNetherlands
-
Jennifer Marler, MDCompletedSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking BehaviorsUnited States
-
Medical University of South CarolinaRecruitingSmoking | Smoking Cessation | Tobacco Smoking | Cigarette SmokingUnited States
-
Ghana Health ServicesKwame Nkrumah University of Science and TechnologyNot yet recruitingSmoking Cessation | Smoking Reduction | Smoking, Tobacco | Smoking Behaviors
Clinical Trials on CSD1905-11
-
Universität des SaarlandesFIFA-Medical Assessment and Research Centre (F-MARC), Zurich, SwitzerlandCompleted
-
University Hospital, GhentCompleted
-
Margaret RagniWyeth is now a wholly owned subsidiary of Pfizer; University of North CarolinaCompletedVon Willebrand DiseaseUnited States
-
Mayo ClinicEnrolling by invitationParkinson Disease | Semantic Dementia | Behavioral Variant of Frontotemporal Dementia | CBD | Apraxia of Speech | MSA - Multiple System Atrophy | FTD | PPA | PSP | PCA | LPA | Semantic AphasiaUnited States
-
NImmune BiopharmaWithdrawnEosinophilic Esophagitis
-
University of PittsburghCompletedHemophilia A | Von Willebrand DiseaseUnited States
-
NImmune BiopharmaCompletedUlcerative ColitisUnited States, Bosnia and Herzegovina, Croatia, Poland, Ukraine
-
Nihon Pharmaceutical Co., LtdCompletedStomach DiseasesJapan
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Not yet recruiting
-
M.D. Anderson Cancer CenterWyeth is now a wholly owned subsidiary of PfizerCompletedLeukemia | Chronic Myeloid Leukemia | Chronic Myelogenous LeukemiaUnited States